Global Specific COX-2 Inhibitors Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Specific COX-2 Inhibitors: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Specific COX-2 Inhibitors Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Etoricoxib
1.2.3 Imrecoxib
1.2.4 Celecoxib
1.2.5 Other
1.3 Market Segmentation by Application
1.3.1 Global Specific COX-2 Inhibitors Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Osteoarthritis and Rheumatoid Arthritis
1.3.3 Dysmenorrhea
1.3.4 Relieve Acute Pain
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Specific COX-2 Inhibitors Revenue Estimates and Forecasts 2020-2031
2.2 Global Specific COX-2 Inhibitors Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Specific COX-2 Inhibitors Sales Estimates and Forecasts 2020-2031
2.4 Global Specific COX-2 Inhibitors Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Specific COX-2 Inhibitors Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Specific COX-2 Inhibitors Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Etoricoxib Market Size by Manufacturers
3.5.2 Imrecoxib Market Size by Manufacturers
3.5.3 Celecoxib Market Size by Manufacturers
3.5.4 Other Market Size by Manufacturers
3.6 Global Specific COX-2 Inhibitors Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Specific COX-2 Inhibitors Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Specific COX-2 Inhibitors Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Specific COX-2 Inhibitors Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Specific COX-2 Inhibitors Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Specific COX-2 Inhibitors Sales and Revenue by Type (2020-2031)
6.4 North America Specific COX-2 Inhibitors Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Specific COX-2 Inhibitors Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Specific COX-2 Inhibitors Sales and Revenue by Type (2020-2031)
7.4 Europe Specific COX-2 Inhibitors Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Specific COX-2 Inhibitors Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Specific COX-2 Inhibitors Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Specific COX-2 Inhibitors Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Specific COX-2 Inhibitors Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Specific COX-2 Inhibitors Sales and Revenue by Type (2020-2031)
9.4 Central and South America Specific COX-2 Inhibitors Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Specific COX-2 Inhibitors Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Specific COX-2 Inhibitors Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Specific COX-2 Inhibitors Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Specific COX-2 Inhibitors Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Organon Pharma
11.1.1 Organon Pharma Corporation Information
11.1.2 Organon Pharma Business Overview
11.1.3 Organon Pharma Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.1.4 Organon Pharma Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Organon Pharma Specific COX-2 Inhibitors Sales by Product in 2024
11.1.6 Organon Pharma Specific COX-2 Inhibitors Sales by Application in 2024
11.1.7 Organon Pharma Specific COX-2 Inhibitors Sales by Geographic Area in 2024
11.1.8 Organon Pharma Specific COX-2 Inhibitors SWOT Analysis
11.1.9 Organon Pharma Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.2.4 Pfizer Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Pfizer Specific COX-2 Inhibitors Sales by Product in 2024
11.2.6 Pfizer Specific COX-2 Inhibitors Sales by Application in 2024
11.2.7 Pfizer Specific COX-2 Inhibitors Sales by Geographic Area in 2024
11.2.8 Pfizer Specific COX-2 Inhibitors SWOT Analysis
11.2.9 Pfizer Recent Developments
11.3 Zentiva
11.3.1 Zentiva Corporation Information
11.3.2 Zentiva Business Overview
11.3.3 Zentiva Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.3.4 Zentiva Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Zentiva Specific COX-2 Inhibitors Sales by Product in 2024
11.3.6 Zentiva Specific COX-2 Inhibitors Sales by Application in 2024
11.3.7 Zentiva Specific COX-2 Inhibitors Sales by Geographic Area in 2024
11.3.8 Zentiva Specific COX-2 Inhibitors SWOT Analysis
11.3.9 Zentiva Recent Developments
11.4 Neopharmed Gentili
11.4.1 Neopharmed Gentili Corporation Information
11.4.2 Neopharmed Gentili Business Overview
11.4.3 Neopharmed Gentili Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.4.4 Neopharmed Gentili Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Neopharmed Gentili Specific COX-2 Inhibitors Sales by Product in 2024
11.4.6 Neopharmed Gentili Specific COX-2 Inhibitors Sales by Application in 2024
11.4.7 Neopharmed Gentili Specific COX-2 Inhibitors Sales by Geographic Area in 2024
11.4.8 Neopharmed Gentili Specific COX-2 Inhibitors SWOT Analysis
11.4.9 Neopharmed Gentili Recent Developments
11.5 Eskayef Pharmaceuticals
11.5.1 Eskayef Pharmaceuticals Corporation Information
11.5.2 Eskayef Pharmaceuticals Business Overview
11.5.3 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.5.4 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales by Product in 2024
11.5.6 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales by Application in 2024
11.5.7 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales by Geographic Area in 2024
11.5.8 Eskayef Pharmaceuticals Specific COX-2 Inhibitors SWOT Analysis
11.5.9 Eskayef Pharmaceuticals Recent Developments
11.6 Zydus
11.6.1 Zydus Corporation Information
11.6.2 Zydus Business Overview
11.6.3 Zydus Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.6.4 Zydus Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Zydus Recent Developments
11.7 Teva
11.7.1 Teva Corporation Information
11.7.2 Teva Business Overview
11.7.3 Teva Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.7.4 Teva Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Teva Recent Developments
11.8 Mylan Pharmaceutical
11.8.1 Mylan Pharmaceutical Corporation Information
11.8.2 Mylan Pharmaceutical Business Overview
11.8.3 Mylan Pharmaceutical Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.8.4 Mylan Pharmaceutical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Mylan Pharmaceutical Recent Developments
11.9 Actavis
11.9.1 Actavis Corporation Information
11.9.2 Actavis Business Overview
11.9.3 Actavis Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.9.4 Actavis Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Actavis Recent Developments
11.10 Jiangsu Hengrui Pharmaceuticals
11.10.1 Jiangsu Hengrui Pharmaceuticals Corporation Information
11.10.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.10.3 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.10.4 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
11.11 Qingdao Baheal Medical
11.11.1 Qingdao Baheal Medical Corporation Information
11.11.2 Qingdao Baheal Medical Business Overview
11.11.3 Qingdao Baheal Medical Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.11.4 Qingdao Baheal Medical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Qingdao Baheal Medical Recent Developments
11.12 Qilu Pharmaceutical
11.12.1 Qilu Pharmaceutical Corporation Information
11.12.2 Qilu Pharmaceutical Business Overview
11.12.3 Qilu Pharmaceutical Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.12.4 Qilu Pharmaceutical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Qilu Pharmaceutical Recent Developments
11.13 Shanxi Tongda Pharmaceutical
11.13.1 Shanxi Tongda Pharmaceutical Corporation Information
11.13.2 Shanxi Tongda Pharmaceutical Business Overview
11.13.3 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.13.4 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Shanxi Tongda Pharmaceutical Recent Developments
11.14 Sichuan Kelun Pharmaceutical
11.14.1 Sichuan Kelun Pharmaceutical Corporation Information
11.14.2 Sichuan Kelun Pharmaceutical Business Overview
11.14.3 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.14.4 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Sichuan Kelun Pharmaceutical Recent Developments
11.15 Jiangsu Chiatai Qingjiang Pharmaceutical
11.15.1 Jiangsu Chiatai Qingjiang Pharmaceutical Corporation Information
11.15.2 Jiangsu Chiatai Qingjiang Pharmaceutical Business Overview
11.15.3 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.15.4 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Jiangsu Chiatai Qingjiang Pharmaceutical Recent Developments
11.16 Beijing Yabao Biological Pharmaceutical
11.16.1 Beijing Yabao Biological Pharmaceutical Corporation Information
11.16.2 Beijing Yabao Biological Pharmaceutical Business Overview
11.16.3 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Models, Descriptions and Specifications
11.16.4 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Beijing Yabao Biological Pharmaceutical Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Specific COX-2 Inhibitors Industry Chain
12.2 Specific COX-2 Inhibitors Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Specific COX-2 Inhibitors Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Specific COX-2 Inhibitors Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Specific COX-2 Inhibitors Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Specific COX-2 Inhibitors Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Specific COX-2 Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Specific COX-2 Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Specific COX-2 Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Specific COX-2 Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Specific COX-2 Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Specific COX-2 Inhibitors Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Specific COX-2 Inhibitors Sales by Region (2020-2025) & (K Units)
Table 8. Global Specific COX-2 Inhibitors Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Specific COX-2 Inhibitors Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Specific COX-2 Inhibitors Sales Share by Manufacturers (2020-2025)
Table 12. Global Specific COX-2 Inhibitors Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Specific COX-2 Inhibitors Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Specific COX-2 Inhibitors by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Specific COX-2 Inhibitors as of 2024)
Table 16. Global Specific COX-2 Inhibitors Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Specific COX-2 Inhibitors Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Specific COX-2 Inhibitors Manufacturing Base and Headquarters
Table 19. Global Specific COX-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Specific COX-2 Inhibitors Sales by Type (2020-2025) & (K Units)
Table 23. Global Specific COX-2 Inhibitors Sales by Type (2026-2031) & (K Units)
Table 24. Global Specific COX-2 Inhibitors Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Specific COX-2 Inhibitors Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Specific COX-2 Inhibitors ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Specific COX-2 Inhibitors Sales by Application (2020-2025) & (K Units)
Table 29. Global Specific COX-2 Inhibitors Sales by Application (2026-2031) & (K Units)
Table 30. Specific COX-2 Inhibitors High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Specific COX-2 Inhibitors Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Specific COX-2 Inhibitors Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Specific COX-2 Inhibitors ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Specific COX-2 Inhibitors Growth Accelerators and Market Barriers
Table 37. North America Specific COX-2 Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Specific COX-2 Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Specific COX-2 Inhibitors Growth Accelerators and Market Barriers
Table 40. Europe Specific COX-2 Inhibitors Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Specific COX-2 Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Specific COX-2 Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Specific COX-2 Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Specific COX-2 Inhibitors Growth Accelerators and Market Barriers
Table 45. Southeast Asia Specific COX-2 Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Specific COX-2 Inhibitors Investment Opportunities and Key Challenges
Table 47. Central and South America Specific COX-2 Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Specific COX-2 Inhibitors Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Specific COX-2 Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Organon Pharma Corporation Information
Table 51. Organon Pharma Description and Major Businesses
Table 52. Organon Pharma Product Models, Descriptions and Specifications
Table 53. Organon Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Organon Pharma Sales Value Proportion by Product in 2024
Table 55. Organon Pharma Sales Value Proportion by Application in 2024
Table 56. Organon Pharma Sales Value Proportion by Geographic Area in 2024
Table 57. Organon Pharma Specific COX-2 Inhibitors SWOT Analysis
Table 58. Organon Pharma Recent Developments
Table 59. Pfizer Corporation Information
Table 60. Pfizer Description and Major Businesses
Table 61. Pfizer Product Models, Descriptions and Specifications
Table 62. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Pfizer Sales Value Proportion by Product in 2024
Table 64. Pfizer Sales Value Proportion by Application in 2024
Table 65. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 66. Pfizer Specific COX-2 Inhibitors SWOT Analysis
Table 67. Pfizer Recent Developments
Table 68. Zentiva Corporation Information
Table 69. Zentiva Description and Major Businesses
Table 70. Zentiva Product Models, Descriptions and Specifications
Table 71. Zentiva Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Zentiva Sales Value Proportion by Product in 2024
Table 73. Zentiva Sales Value Proportion by Application in 2024
Table 74. Zentiva Sales Value Proportion by Geographic Area in 2024
Table 75. Zentiva Specific COX-2 Inhibitors SWOT Analysis
Table 76. Zentiva Recent Developments
Table 77. Neopharmed Gentili Corporation Information
Table 78. Neopharmed Gentili Description and Major Businesses
Table 79. Neopharmed Gentili Product Models, Descriptions and Specifications
Table 80. Neopharmed Gentili Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Neopharmed Gentili Sales Value Proportion by Product in 2024
Table 82. Neopharmed Gentili Sales Value Proportion by Application in 2024
Table 83. Neopharmed Gentili Sales Value Proportion by Geographic Area in 2024
Table 84. Neopharmed Gentili Specific COX-2 Inhibitors SWOT Analysis
Table 85. Neopharmed Gentili Recent Developments
Table 86. Eskayef Pharmaceuticals Corporation Information
Table 87. Eskayef Pharmaceuticals Description and Major Businesses
Table 88. Eskayef Pharmaceuticals Product Models, Descriptions and Specifications
Table 89. Eskayef Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Eskayef Pharmaceuticals Sales Value Proportion by Product in 2024
Table 91. Eskayef Pharmaceuticals Sales Value Proportion by Application in 2024
Table 92. Eskayef Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 93. Eskayef Pharmaceuticals Specific COX-2 Inhibitors SWOT Analysis
Table 94. Eskayef Pharmaceuticals Recent Developments
Table 95. Zydus Corporation Information
Table 96. Zydus Description and Major Businesses
Table 97. Zydus Product Models, Descriptions and Specifications
Table 98. Zydus Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Zydus Recent Developments
Table 100. Teva Corporation Information
Table 101. Teva Description and Major Businesses
Table 102. Teva Product Models, Descriptions and Specifications
Table 103. Teva Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Teva Recent Developments
Table 105. Mylan Pharmaceutical Corporation Information
Table 106. Mylan Pharmaceutical Description and Major Businesses
Table 107. Mylan Pharmaceutical Product Models, Descriptions and Specifications
Table 108. Mylan Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Mylan Pharmaceutical Recent Developments
Table 110. Actavis Corporation Information
Table 111. Actavis Description and Major Businesses
Table 112. Actavis Product Models, Descriptions and Specifications
Table 113. Actavis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Actavis Recent Developments
Table 115. Jiangsu Hengrui Pharmaceuticals Corporation Information
Table 116. Jiangsu Hengrui Pharmaceuticals Description and Major Businesses
Table 117. Jiangsu Hengrui Pharmaceuticals Product Models, Descriptions and Specifications
Table 118. Jiangsu Hengrui Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 120. Qingdao Baheal Medical Corporation Information
Table 121. Qingdao Baheal Medical Description and Major Businesses
Table 122. Qingdao Baheal Medical Product Models, Descriptions and Specifications
Table 123. Qingdao Baheal Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Qingdao Baheal Medical Recent Developments
Table 125. Qilu Pharmaceutical Corporation Information
Table 126. Qilu Pharmaceutical Description and Major Businesses
Table 127. Qilu Pharmaceutical Product Models, Descriptions and Specifications
Table 128. Qilu Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Qilu Pharmaceutical Recent Developments
Table 130. Shanxi Tongda Pharmaceutical Corporation Information
Table 131. Shanxi Tongda Pharmaceutical Description and Major Businesses
Table 132. Shanxi Tongda Pharmaceutical Product Models, Descriptions and Specifications
Table 133. Shanxi Tongda Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Shanxi Tongda Pharmaceutical Recent Developments
Table 135. Sichuan Kelun Pharmaceutical Corporation Information
Table 136. Sichuan Kelun Pharmaceutical Description and Major Businesses
Table 137. Sichuan Kelun Pharmaceutical Product Models, Descriptions and Specifications
Table 138. Sichuan Kelun Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Sichuan Kelun Pharmaceutical Recent Developments
Table 140. Jiangsu Chiatai Qingjiang Pharmaceutical Corporation Information
Table 141. Jiangsu Chiatai Qingjiang Pharmaceutical Description and Major Businesses
Table 142. Jiangsu Chiatai Qingjiang Pharmaceutical Product Models, Descriptions and Specifications
Table 143. Jiangsu Chiatai Qingjiang Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. Jiangsu Chiatai Qingjiang Pharmaceutical Recent Developments
Table 145. Beijing Yabao Biological Pharmaceutical Corporation Information
Table 146. Beijing Yabao Biological Pharmaceutical Description and Major Businesses
Table 147. Beijing Yabao Biological Pharmaceutical Product Models, Descriptions and Specifications
Table 148. Beijing Yabao Biological Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 149. Beijing Yabao Biological Pharmaceutical Recent Developments
Table 150. Key Raw Materials Distribution
Table 151. Raw Materials Key Suppliers
Table 152. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 153. Milestones in Production Technology Evolution
Table 154. Distributors List
Table 155. Market Trends and Market Evolution
Table 156. Market Drivers and Opportunities
Table 157. Market Challenges, Risks, and Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources


List of Figures
Figure 1. Specific COX-2 Inhibitors Product Picture
Figure 2. Global Specific COX-2 Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Etoricoxib Product Picture
Figure 4. Imrecoxib Product Picture
Figure 5. Celecoxib Product Picture
Figure 6. Other Product Picture
Figure 7. Global Specific COX-2 Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Osteoarthritis and Rheumatoid Arthritis
Figure 9. Dysmenorrhea
Figure 10. Relieve Acute Pain
Figure 11. Other
Figure 12. Specific COX-2 Inhibitors Report Years Considered
Figure 13. Global Specific COX-2 Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 15. Global Specific COX-2 Inhibitors Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Specific COX-2 Inhibitors Revenue Market Share by Region (2020-2031)
Figure 17. Global Specific COX-2 Inhibitors Sales (2020-2031) & (K Units)
Figure 18. Global Specific COX-2 Inhibitors Sales (CAGR) by Region (2020-2031) (K Units)
Figure 19. Global Specific COX-2 Inhibitors Sales Market Share by Region (2020-2031)
Figure 20. Top 5 and Top 10 Manufacturers Specific COX-2 Inhibitors Sales Volume Market Share in 2024
Figure 21. Global Specific COX-2 Inhibitors Revenue Market Share Ranking (2024)
Figure 22. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 23. Etoricoxib Revenue Market Share by Manufacturer in 2024
Figure 24. Imrecoxib Revenue Market Share by Manufacturer in 2024
Figure 25. Celecoxib Revenue Market Share by Manufacturer in 2024
Figure 26. Other Revenue Market Share by Manufacturer in 2024
Figure 27. Global Specific COX-2 Inhibitors Sales Market Share by Type (2020-2031)
Figure 28. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2020-2031)
Figure 29. Global Specific COX-2 Inhibitors Sales Market Share by Application (2020-2031)
Figure 30. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2020-2031)
Figure 31. North America Specific COX-2 Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 32. North America Specific COX-2 Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 33. North America Top 5 Manufacturers Specific COX-2 Inhibitors Sales Revenue (US$ Million) in 2024
Figure 34. North America Specific COX-2 Inhibitors Sales Volume (K Units) by Type (2020- 2031)
Figure 35. North America Specific COX-2 Inhibitors Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 36. North America Specific COX-2 Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 37. North America Specific COX-2 Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 38. US Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 39. Canada Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 40. Mexico Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 41. Europe Specific COX-2 Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 42. Europe Specific COX-2 Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 43. Europe Top 5 Manufacturers Specific COX-2 Inhibitors Sales Revenue (US$ Million) in 2024
Figure 44. Europe Specific COX-2 Inhibitors Sales Volume (K Units) by Type (2020-2031)
Figure 45. Europe Specific COX-2 Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 46. Europe Specific COX-2 Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 47. Europe Specific COX-2 Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 48. Germany Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 49. France Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 50. U.K. Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 51. Italy Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 52. Russia Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 53. Asia-Pacific Specific COX-2 Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 54. Asia-Pacific Specific COX-2 Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Asia-Pacific Top 8 Manufacturers Specific COX-2 Inhibitors Sales Revenue (US$ Million) in 2024
Figure 56. Asia-Pacific Specific COX-2 Inhibitors Sales Volume (K Units) by Type (2020- 2031)
Figure 57. Asia-Pacific Specific COX-2 Inhibitors Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 58. Asia-Pacific Specific COX-2 Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 59. Asia-Pacific Specific COX-2 Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 60. Indonesia Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 61. Japan Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 62. South Korea Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 63. China Taiwan Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 64. India Specific COX-2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 65. Central and South America Specific COX-2 Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 66. Central and South America Specific COX-2 Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 67. Central and South America Top 5 Manufacturers Specific COX-2 Inhibitors Sales Revenue (US$ Million) in 2024
Figure 68. Central and South America Specific COX-2 Inhibitors Sales Volume (K Units) by Type (2021-2031)
Figure 69. Central and South America Specific COX-2 Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 70. Central and South America Specific COX-2 Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 71. Central and South America Specific COX-2 Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 72. Brazil Specific COX-2 Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 73. Argentina Specific COX-2 Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 74. Middle East, and Africa Specific COX-2 Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 75. Middle East and Africa Specific COX-2 Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 76. Middle East and Africa Top 5 Manufacturers Specific COX-2 Inhibitors Sales Revenue (US$ Million) in 2024
Figure 77. Middle East and Africa Specific COX-2 Inhibitors Sales Volume (K Units) by Type (2021-2031)
Figure 78. South America Specific COX-2 Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 79. Middle East and Africa Specific COX-2 Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 80. Middle East and Africa Specific COX-2 Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 81. GCC Countries Specific COX-2 Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 82. Turkey Specific COX-2 Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 83. Egypt Specific COX-2 Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 84. South Africa Specific COX-2 Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 85. Specific COX-2 Inhibitors Industry Chain Mapping
Figure 86. Regional Specific COX-2 Inhibitors Manufacturing Base Distribution (%)
Figure 87. Global Specific COX-2 Inhibitors Production Market Share by Region (2020-2031)
Figure 88. Specific COX-2 Inhibitors Production Process
Figure 89. Regional Specific COX-2 Inhibitors Production Cost Structure
Figure 90. Channels of Distribution (Direct Vs Distribution)
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit